Translational research is the application of discoveries made in the laboratory to the development of novel drugs, vaccines, and diagnostic tools. The Rockefeller University and its renowned research hospital have integrated their strengths to create one of the world’s leading centers for translational research.
Protocols now under way at The Rockefeller University Hospital include patient-based studies of cancer, heart disease, diabetes, autoimmunity, Alzheimer’s, infectious diseases, and a range of additional disorders. Rockefeller scientists are investigating the genetic underpinnings of human disease as well as the contributions of non-hereditary factors, such as nutrition and the microbiome.
In recent years, the University and Hospital have built a robust translational pipeline that provides investigators with the resources they need to take their discoveries from the laboratory bench to the research clinic. This “bench to bedside” pipeline has helped many basic science labs to make their first forays into patient-based research. These unprecedented efforts have been a great success. More than one third of Rockefeller laboratories headed by Ph.D. scientists now have protocols involving human subjects—and many labs have more than one. The University’s basic science labs are now running nearly 80 human subjects protocols, a dramatic increase from 2008, when there were fewer than ten.
The Rockefeller University offers a range of giving opportunities for philanthropists interested in translational research. These include competitively awarded pilot grants to launch new patient-based studies. Pilot projects are aimed at understanding the fundamental causes of disease and generating information that points the way to new treatment strategies. Click here for a full list of conditions under study at the University.